Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

Become a member
  1. OncologyPRO
  2. Meeting Resources
  3. ESMO Virtual Congress 2020

New drugs in development: What will be approved in 2025?

Epigenetic drugs: EZH2, BET and LDSD1

Date

17 Oct 2020

Session

New drugs in development: What will be approved in 2025?

Topics

Translational Research

Tumour Site

Presenters

Sophie Postel-Vinay

Authors

S. Postel-Vinay

Author affiliations

  • Drug Development Department, Institut Gustave Roussy, 94805 - Villejuif/FR

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Login

Resources from the same session

FGFR inhibitors

Presenter: Yohann Loriot

Session: New drugs in development: What will be approved in 2025?

Resources:

Slides

Webcast

Antibody Drug Conjugate (ADC)

Presenter: Victor Moreno Garcia

Session: New drugs in development: What will be approved in 2025?

Resources:

Slides

Webcast

Q&A and live discussion

Presenter: Jordi Rodon

Session: New drugs in development: What will be approved in 2025?

Resources:

Webcast

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings

  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.